Over the last 10 years, every aspect of continuing medical education (CME) has endured major changes, forcing several pharmaceutical companies to reassess their future position in this important industry sector. Consider these facts:
So what role could or should the pharmaceutical industry play in medical education for healthcare professionals? And what should it expect in return for its investments? Find out in one convenient, compelling new FirstWord Dossier report: Pharma’s Future Role in CME.
Save time and effort by reviewing forecasts from 10 leading figures in the US and European CME fields. In this report, they analyse the emerging trends, radical changes, and major risks affecting future medical education. These opinion leaders also examine whether it would be better for the industry to take a leading role in future CME productions, or strategically direct these from the background.
Key Report Features
Key Questions Answered
Who Would Benefit From This Report?
This report will be of value to pharma directors and managers with responsibilities in the following areas:
This report also will be of value to medical device companies, as well as medical education and clinical communications agencies.
Expert Views Include:
“I hope that we will find how to have similar rules all over the world. The big problem nowadays is that you have different rules in the US, in Canada, in Europe, in different Member States. It makes it very difficult because how can you comply with all the legislations?” Dr Bernard Maillet, treasurer, VBS-GBS
“Everyone should take a long hard look at the dollars they're investing in CME, and why they're investing it. If their answer is to sell more products then they shouldn’t be in it. If their answer is to improve patient care then they’re in the right place,” Maureen Doyle-Scharff, Senior Director, Medical Education Group, Pfizer
“Currently several pharmaceutical companies are aligning themselves to IME education. Some companies are grouping CME and IME together,” David Noble, Global Head, PeerVoice
“The absolute critical thing that must happen with pharma is the budgets for CME must be taken away from marketing. The top 10 pharma companies are set up to hand over money from the marketing department to [regulations and legal departments],” Eugene Pozniak, programme director, European CME Forum
Table of Contents
for Pharma's Future Role in CME
3.Industry pushed towards the side-lines
3.1. From dark days to Sunshine Act
3.2. Minimising risk is the new priority
3.3. Europe following the US model
3.4. European disunion?
3.5. The push for new European guidelines
3.6. Crossing borders
4.Sharing the responsibility of medical education
4.1. Increased risk, reduced funding
4.2. Collaborative approaches in CME
4.3. Other potential sources of funding
4.4. Should physicians be responsible for their own medical education?
4.5. Evaluating IME vs CME
4.6. So what are the differences between CME and IME?
4.7. Regulating IME
4.8. Industry involvement in IME
4.9. How medical education providers are having to adapt?
4.10. The grants system: Help or hindrance?
4.11. The logistical challenge
5.1. What is the ROI for industry?
5.2. Improving patient outcomes
5.3. Internal structures altering
5.4. Is the quality of CME improving?
5.5. The benefits of e-learning
Number of Pages
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.